SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks

    Gouya L (1), Ventura P (2), Balwani M (3), Bissell DM (4), Rees DC (5), Stölzel U (6), Phillips JD (7), Kauppinen R (8), Langendonk JG (9), Desnick RJ (3), Deybach JC (1), Bonkovsky HL (10), Parker C (7), Naik H (3), Badminton M (11), Stein PE (5), Minder E (12), Windyga J (13), Bruha R (14), Cappellini MD (15), Sardh E (16), Harper P (16), Sandberg S (17), Aarsand AK (17), Andersen J (17), Alegre F (18), Ivanova A (19), Talbi N (20), Chan A (21), Querbes W (21), Ko J (21), Penz C (21), Liu S (21), Lin T (21), Simon A (21), Anderson KE (22).

    (1) Centre de Référence Maladies Rares Porphyries, Colombes, France.
    (2) Università degli Studi di Modena e Reggio Emilia, Emilia-Romagna, Italy.
    (3) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (4) University of California, San Francisco, CA, USA.
    (5) King's College Hospital, King's College London, London, UK.
    (6) Klinikum Chemnitz Porphyria Center, Chemnitz, Germany.
    (7) University of Utah, Salt Lake City, UT, USA.
    (8) University Hospital of Helsinki, Helsinki, Finland.
    (9) Porphyria Center, Center for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
    (10) Section on Gastroenterology & Hepatology, Wake Forest University/NC Baptist Medical Center, Winston-Salem, NC, USA.
    (11) University Hospital of Wales, Cardiff, UK.
    (12) Stadtspital Triemli, Zentrallabor, Zurich, Switzerland.
    (13) Department of Hemostatic Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
    (14) 4th internal clinic, General University Hospital, Charles University, Prague, Czech republic.
    (15) University of Milan, Fondazione IRCCS, Ca Granda, Milan, Italy.
    (16) Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
    (17) Norwegian Porphyria Centre, Haukeland University Hospital, Bergen, Norway.
    (18) Clinica Universidad de Navarra, Navarra, Spain.
    (19) St. Ivan Rilski U Hospital, Sofia, Bulgaria.
    (20) Laboratory of Excellence GR-Ex, University of Paris, Paris, France.
    (21) Alnylam Pharmaceuticals, Cambridge, MA, USA.
    (22) University of Texas Medical Branch, Galveston, TX, USA

    Hepatology 12 SEPTEMBER 2019

  • Emphysema phenotypes and lung cancer risk

    González J (1), Henschke CI (2), Yankelevitz DF (2), Seijo LM (1), Reeves AP (3,4), Yip R (2), Xie Y (3), Chung M (2), Sánchez-Salcedo P (5), Alcaide AB (1), Campo A (1), Bertó J (1), Del Mar Ocón M (1), Pueyo J (6), Bastarrika G (6), de-Torres JP (1,7), Zulueta JJ (1,7,8,9).

    (1) Pulmonary Service, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Department of Radiology Mount Sinai School of Medicine, NY, United States of America.
    (3) School of Electrical and Computer Engineering, Cornell University, Ithaca, NY, United States of America.
    (4) Vision, Inc, Ithaca, NY, United States of America.
    (5) Pulmonary Service, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (6) Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Navarra's Health Research Institute (IDISNA), Pamplona, Spain.
    (8) CIBERONC, ISCIII, Madrid, Spain.
    (9) VisionGate, Inc, Phoenix, Arizona, United States of America.

    PLoS One 25 JULY 2019

  • Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation

    Idoate Grijalba AI (1), Aldaz Pastor A (2), Marquet P (3,4,5), Woillard JB (3,4,5).

    (1) Pharmacy department, Clinica Universidad de Navarra, 31008, Pamplona, Spain.
    (2) Pharmacy department, Clinica Universidad de Navarra, 31008, Pamplona, Spain.
    (3) IPPRITT, Univ. Limoges, F-87000, Limoges, France.
    (4) IPPRITT, INSERM, U1248, F-87000, Limoges, France.
    (5) CHU Limoges, F-87000, Limoges, France.

    European Journal of Clinical Pharmacology 23 JULY 2019

  • Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

    Corral J (1), Mok TS (2), Nakagawa K (3), Rosell R (4), Lee KH (5), Migliorino MR (6), Pluzanski A (7), Linke R (8), Devgan G (9), Tan W (10), Quinn S (11), Wang T (12), Wu YL (13).

    (1) Clínica Universidad de Navarra, Madrid, 28027, Spain.
    (2) State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.
    (3) Kindai University Hospital, Osaka, 589-8511, Japan.
    (4) Catalan Institute of Oncology, Barcelona, Spain.
    (5) Chungbuk National University Hospital, Cheongju, Korea.
    (6) Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, 00152, Italy.
    (7) The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, Warsaw, 02-781, Poland.
    (8) SFJ Pharmaceuticals®, Pleasanton, CA 94588, USA.
    (9) Pfizer Oncology, New York, NY 10017, USA.
    (10) Pfizer Clinical Pharmacology, San Diego, CA 92121, USA.
    (11) Pfizer Oncology, Cambridge, MA 02139, USA.
    (12) Pfizer Oncology, Groton, CT 06340, USA.
    (13) Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.

    Future Oncology 17 JULY 2019

  • Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer

    Duruisseaux M (1), Martínez-Cardús A (2), Calleja-Cervantes ME (2), Moran S (2), Castro de Moura M (2), Davalos V (2), Piñeyro D (2), Sanchez-Cespedes M (2), Girard N (3), Brevet M (4), Giroux-Leprieur E (5), Dumenil C (6), Pradotto M (7), Bironzo P (7), Capelletto E (7), Novello S (7), Cortot A (8), Copin MC (9), Karachaliou N (10), Gonzalez-Cao M (11), Peralta S (12), Montuenga LM (13), Gil-Bazo I (14), Baraibar I (15), Lozano MD (16), Varela M (17), Ruffinelli JC (18), Palmero R (18), Nadal E (18), Moran T (19), Perez L (20), Ramos I (21), Xiao Q (22), Fernandez AF (23), Fraga MF (24), Gut M 25, Gut I (25), Teixidó C (26), Vilariño N (27), Prat A (27), Reguart N (27), Benito A (28), Garrido P (29), Barragan I (30), Emile JF (31), Rosell R (32), Brambilla E (33), Esteller M (34)

    (1) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain; Department of Respiratory Medicine, Groupement Hospitalier Est, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, France.
    (2) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain.
    (3) Department of Respiratory Medicine, Groupement Hospitalier Est, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, France.
    (4) Department of Pathology, Centre de biologie et pathologie Est, Institut de Cancérologie des Hospices Civils de Lyon, Université Lyon 1, Lyon, France.
    (5) Department of Respiratory Diseases and Thoracic Oncology, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France; EA4340, UVSQ, University Paris-Saclay, Boulogne-Billancourt, France.
    (6) Department of Respiratory Diseases and Thoracic Oncology, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France.
    (7) Department of Oncology, University of Turin, AOU San Luigi, Turin, Italy.
    (8) Thoracic Oncology Department, CHU Lille, University of Lille, Lille, France; UMR 8161-M3T-Mechanisms of Tumorigenesis and Targeted Therapies, CNRS, Institut Pasteur de Lille, University of Lille, Lille, France.
    (9) Department of Pathology, CHU Lille, University of Lille, Lille, France.
    (10) Medical Oncology Service, Institute of Oncology Rosell, University Hospital Sagrat Cor, QuironSalud Group, Barcelona, Spain.
    (11) Medical Oncology Service, Quirón Dexeus University Hospital, Barcelona, Catalonia, Spain.
    (12) Medical Oncology Service, University Hospital Sant Joan de Reus, Reus, Spain.
    (13) Program in Solid Tumors and Biomarkers, Center for Applied Medical Research, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (14) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (15) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain.
    (16) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (17) Pathology Department, University Hospital Bellvitge, Barcelona, Spain.
    (18) Medical Oncology Department, Catalan Institute of Oncology, Hospital Duran I Reynals, Barcelona, Spain.
    (19) Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain.
    (20) Department of Pathology, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain.
    (21) Medical Oncology Service, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain.
    (22) Pharmacoepigenetics Group, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
    (23) Cancer Epigenetics Laboratory, Institute of Oncology of Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain; Fundación para la Investigación Biosanitaria de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
    (24) Nanomaterials & Nanotechnology Research Center, Universidad de Oviedo, Oviedo, Spain.
    (25) CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
    (26) Pathology Department, Hospital Clinic, Institut d'Investigacions Biomédiques August Pi i Sunyer, Barcelona, Spain.
    (27) Medical Oncology Department, Hospital Clinic, Institut d'Investigacions Biomédiques August Pi i Sunyer, Barcelona, Spain.
    (28) Pathology Department, University Hospital Ramon y Cajal, Madrid, Spain.
    (29) Medical Oncology Service, University Hospital Ramon y Cajal, Madrid, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (30) Medical Oncology Service, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain; Pharmacoepigenetics Group, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
    (31) Department of Pathology Department, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France.
    (32) Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Barcelona, Spain.
    (33) Centre Hospitalier Grenoble, INSERM U1219, University UGA, Grenoble, France.
    (34) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, Spain; Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Spain.

    The Lancet. Respiratory Medicine 06 JULY 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra